MTD vs. ONC: Mettler-Toledo vs. BeOne Medicines Stock Comparison

Company Profile

Mettler-Toledo (MTD) and BeOne Medicines (ONC) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but MTD is classified in Life Sciences Tools & Services while ONC is classified in Biotechnology.

Mettler-Toledo (MTD) trades as ordinary local shares, while BeOne Medicines (ONC) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Capital efficiency shows on one side only: BeOne Medicines (ONC) earns 18.40% on shareholders’ equity, ranked against its industry; Mettler-Toledo (MTD) has no ROE this period.

Mettler-Toledo (MTD) at 22.25% keeps the most of each sales dollar — above its industry’s net margin range — and BeOne Medicines (ONC) at 13.86% also retains a top-quartile share.

Both Mettler-Toledo (MTD) at 28.70% and BeOne Medicines (ONC) at 22.15% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

Profitability Metrics

Growth

Both Mettler-Toledo (MTD) at 3.98% and BeOne Medicines (ONC) at 40.23% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Only one side can be read here: Mettler-Toledo (MTD) reports EPS growth of 3.88%, ranked against its industry; BeOne Medicines (ONC) has no EPS growth figure this period.

Growth Metrics

Financial Strength

BeOne Medicines (ONC) at 3.55 keeps current ratio within its industry’s typical mid-range, while Mettler-Toledo (MTD) at 1.10 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for MTD.

BeOne Medicines (ONC) at 0.35 is near its industry mid-range for debt-to-equity ratio, while Mettler-Toledo (MTD) at 26.06 sits above its benchmark range, pointing to a heavier debt load relative to equity.

Financial Strength Metrics

Dividends

Neither Mettler-Toledo (MTD) nor BeOne Medicines (ONC) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Neither Mettler-Toledo (MTD) nor BeOne Medicines (ONC) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Dividend Metrics

Valuation

Mettler-Toledo (MTD) at 37.38 is near its industry’s usual P/E ratio, while BeOne Medicines (ONC) at 52.17 sits in the richer quartile — ONC needs stronger growth or earnings quality to justify the premium.

On P/S ratio, both Mettler-Toledo (MTD) at 8.16 and BeOne Medicines (ONC) at 7.04 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

Both look rich against book: BeOne Medicines (ONC) at 7.98 sits in the upper P/B ratio quartile, and Mettler-Toledo (MTD) at 442.71 prices even higher, above its industry range.

Valuation Metrics